

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/53</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/11699</b> <b>(43) International Publication Date:</b> 3 April 1997 (03.04.97)
<b>(21) International Application Number:</b> PCT/US96/13550 <b>(22) International Filing Date:</b> 21 August 1996 (21.08.96) <b>(30) Priority Data:</b> 08/533,424 25 September 1995 (25.09.95) US <b>(71) Applicant:</b> SANOFI WINTHROP INC. [US/US]; 90 Park Avenue, New York, NY 10016 (US). <b>(72) Inventors:</b> BROWN, Stephen; 17 The Croft, Ulgham, Morpeth, Northumberland NE61 3BB (GB). BAKER, Edward; 3 Bradshawgate, North Farm, Swinhoe, Chathill, Northumberland NE67 5AA (GB). <b>(74) Agent:</b> DAVIS, William, J.; Sanofi Inc., 9 Great Valley Parkway, Malvern, PA 19355 (US).	<b>(81) Designated States:</b> AU, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, RU, SG, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> 1,2,4-BENZOTRIAZINE OXIDES FORMULATIONS <b>(57) Abstract</b> <p>Disclosed are aqueous parenteral formulations for the treatment of cancer tumors comprising 1,2,4-benzotriazine-3-amine 1,4-dioxides in a citrate buffer, and method of cancer tumor treatment.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## 1,2,4-BENZOTRIAZINE OXIDES FORMULATIONS

BACKGROUND OF THE INVENTION


5

Field of the Invention

The present invention relates to the field of treatments for cancer tumors. More particularly, the present invention relates to treatment of cancer tumors with 1,2,4-benzotriazine oxides contained in an aqueous buffered vehicle.

Reported Developments

1,2,4-Benzotriazine oxides are known compounds. U.S. Patent No. 3,980,779 discloses 3-amino-1,2,4-benzotriazine-1,4-di-oxide compositions having the formula



wherein

one of R and R' is hydrogen, halogen, lower alkyl, halo (lower alkyl), lower alkoxy, carbamoyl, sulfonamido, carboxy or carbo (lower alkoxy) and the other of R and R' is halogeno, lower alkyl, halo (lower alkyl), lower alkoxy, carbamoyl, sulfonamido, carboxy or carbo (lower alkoxy),

as antimicrobial composition used to promote livestock growth.

U.S. Patent, 5,175,287 issued December 29, 1992 discloses the use of 1,2,4-benzotriazine oxides in conjunction with radiation for treatment of tumors. The 1,2,4-benzotriazine oxides sensitize the tumor cells to radiation and make them more amenable to this treatment modality.

Holden et al (1992) "Enhancement of Alkylating Agent Activity by SR-4233 in the FSAIC Murine Fibrosarcoma" JNCI 84: 187-193 discloses the use of SR-4233, namely 3-amino-1,2,4-benzotriazine-1,4-dioxide, also known and hereinafter sometimes referred to as tirapazamine, in combination with an antitumor alkylating agent. The four antitumor alkylating agents, cisplatin, cyclophosphamide, carmustine and melphalan, were each tested to examine the ability of tirapazamine to overcome the resistance of hypoxic tumor cells to antitumor alkylating agents. Tirapazamine was tested alone and in combination with varying amounts of each of the antitumor alkylating agents. When SR-4233 was administered just before single-dose treatment with cyclophosphamide, carmustine or melphalan marked dose enhancement leading to synergistic cytotoxic effects on tumor cells was observed.

International Application No. PCT/US89/01037 discloses 1,2,4-benzotriazine oxide as radiosensitizers and selective cytotoxic agents. Other related patents include: U.S. Patent Nos. 3,868,372 and 4,001,410 which disclose the preparation of 1,2,4-benzotriazine oxides; and U.S. Patent Nos. 3,991,189 and 3,957,799 which disclose derivatives of 1,2,4-benzotriazine oxides.

Members of 1,2,4-benzotriazine oxides have been found to be effective in the treatment of cancer tumors when used in conjunction with radiation therapy and chemotherapy.

Radiation therapy and chemotherapy, along with surgery, remain the three primary modalities in the treatment of cancer. Radiation therapy and chemotherapy function as alternatives to surgery in the primary control of a variety of neoplasms, where surgery is limited by anatomic consideration. Current knowledge demonstrates that higher cure rates and greater quality of life could be afforded to cancer patients if the effectiveness of radiation therapy and chemotherapy were improved.

One way to improve the effectiveness of radiotherapy or chemotherapy is to take advantage of the hypoxia that exists in tumors - one of the few exploitable difference between normal and tumor tissues. Abnormal development of blood vessels is characteristic of a large number of solid tumors. This abnormal capillary system often results in areas of hypoxia, transient or permanent. In general, hypoxia increases the resistance of a cell, normal or cancerous, to therapy. A method that augments the kill of hypoxic tumor cells (or limits the

radiation damage to normal tissues) would improve the therapeutic index of radiation or chemotherapy.

The benzotriazine compounds have been developed to take advantage of this relative hypoxia within the tumor. Tirapazamine, the most promising member of the benzotriazine series to date, is bioreduced under conditions of hypoxia to an active intermediate. This active intermediate can induce DNA damage, which enhances the effects of radiation therapy or chemotherapy and is cytotoxic in its own right. Because adjacent normal tissues are not hypoxic, this bioreduction allows for selective cytotoxic effects on hypoxic tumor cells.

Research has indicated substantial superiority of the benzotriazines over nitroimidazole radiation sensitizers and other bioreductive agents *in vitro* as shown in Table I.

TABLE I

Hypoxic Cytotoxicity Ratios For Various Bioreductive Drugs *In Vitro*

Bioreductive Agent (and type)	Hypoxic Cytotoxicity Ratio <sup>a</sup>	
	Rodent	Human
Tirapazamine (Benzotriazine di-N-oxide)	75-200	15-100
RSU-1069 (Nitroimidazole/Aziridine)	75-100	10-20
Misonidazole (Nitroimidazole)	10-15	15
Porfiromycin (Quinone)	5-10	~10
Nitracrine (Nitroacridine)	7	--
Mitomycin C (Quinone)	1-5	1-2

<sup>a</sup> Hypoxic cytotoxicity ratio = For equivalent levels of cell killing, the ratio of the drug concentration required under aerobic conditions vs. under hypoxic conditions.

Tirapazamine, however, has the drawbacks of insufficient solubility in pharmaceutical vehicles suitable for parenteral administration as well as being unstable in such vehicles. It has been found that the solubility of tirapazamine in water is about 0.81 mg/ml, which would require a large volume of the solution, approximately, 1 liter, to be administered to a patient for providing the proper dose. Attempts to enhance the solubility using surfactants such as Tween 80, and polymers such as Pluronic F68, Povidone and Albumin were unsuccessful with minimal increase in solubility. Solubility enhancement with co-solvents was more

successful, however, the proportion of co-solvents necessary to solubilize the expected minimum tolerated dose of tirapazamine would mean infusing significant quantities of co-solvents, for example, up to 120 ml propylene glycol as a 50% v/v propylene glycol/aqueous solution. This large volume of a co-solvent is undesirable in an injectable formulation and risks unwanted clinical affects in a patient.

Tirapazamine also lacks stability on shelf-life: complete degradation occurs after refluxing for less than four hours in 0.1 N sodium hydroxide.


The present invention has as its main object to provide an aqueous infusable/injectable formulation which contains sufficient amounts of the anticancer tumor agent and is stable on shelf-life. During our extensive clinical studies of tirapazamine it was realized that without sufficient solubility and stability this very promising drug would not help the countless patients suffering from cancer tumor.

15

SUMMARY OF THE INVENTION

The present invention provides an aqueous parenteral formulation for the treatment of cancer tumors comprising:

- 5 an effective cancer tumor treating amount of a compound of the formula (I)



- wherein X is H; hydrocarbyl (1-4C); hydrocarbyl (1-4C) substituted with OH, NH<sub>2</sub>, NHR or  
 10 NRR; halogen; OH; alkoxy (1-4C); NH<sub>2</sub>; NHR or NRR; wherein each R is independently  
 selected from lower alkyl (1-4C) and lower acyl (1-4C) and lower alkyl (1-4C) and lower  
 acyl (1-4C) substituted with OH, NH<sub>2</sub>, alkyl (1-4C) secondary and dialkyl (1-4C) tertiary  
 amino groups, alkoxy (1-4C) or halogen; and when X is NRR, both R's taken together  
 directly or through a bridge oxygen to form a morpholino ring, pyrrolidino ring or piperidino  
 15 ring;

n is 0 or 1; and

- Y<sup>1</sup> and Y<sup>2</sup> are independently either H; nitro; halogen; hydrocarbyl (1-14C) including  
 cyclic and unsaturated hydrocarbyl, optionally substituted with 1 or 2 substituents selected  
 from the group consisting of halogen, hydroxy, epoxy, alkoxy (1-4C), alkylthio (1-4C),  
 20 primary amino (NH<sub>2</sub>), alkyl (1-4C) secondary amino, dialkyl (1-4C) tertiary amino, dialkyl  
 (1-4C) tertiary amino where the two alkyls are linked together to produce a morpholino,  
 pyrrolidino or piperidino, acyloxy (1-4C), acylamido (1-4C) and thio analogs thereof,  
 acetlaminoalkyl (1-4C), carboxy, alkoxycarbonyl (1-4C), carbamyl, alkylcarbamyl (1-4C),  
 alkylsulfonyl (1-4C) or alkylphosphonyl (1-4C), wherein the hydrocarbyl can optionally be  
 25 interrupted by a single ether (-O-) linkage; or wherein Y<sup>1</sup> and Y<sup>2</sup> are independently either  
 morpholino, pyrrolidino, piperidino, NH<sub>2</sub>, NHR', NRR'O(CO)R', NH(CO)R', O(SO)R', or  
 O(POR')R' in which R' is a hydrocarbyl (1-4C) which may be substituted with OH, NH<sub>2</sub>,  
 alkyl (1-4C) secondary amino, dialkyl (1-4C) tertiary amino, morpholino, pyrrolidino,  
 piperidino, alkoxy (1-4C), or halogen substituents, or pharmacologically acceptable salt of

said compound in a parenterally acceptable buffer having a concentration of from about 0.001M to about 0.1M.

More particularly, the parenteral formulation for the treatment of cancer tumors of the present invention comprises:

5

of from about 0.500 to about 0.810 g of a compound of the formula (I);

of from about 0.100 to about 9.000 g of sodium chloride;

10


of from about 0.1 to about 10.00 g of citric acid;

of from about 0.02 to about 3.00 g of sodium hydroxide; and

qs to pH 3.0 - 5.0 in water to 1000 ml.

15

The preferred anticancer tumor compound of the present invention is tirapazamine, 1,2,4-benzotriazine-3-amine 1,4-dioxide, having the structural formula



20

with molecular weight of 178.16 and melting point on decomposition of 220°C.

In the most preferred intravenous formulation each milliliter of solution contains from about 0.7 to about 0.81 mg/ml tirapazamine in an isotonic citrate buffer having a pH of from about 3.7 to about 4.3.

25

The present invention is also directed to a method of cancer tumor treatment of a patient in need of such treatment comprising administering an effective cancer tumor treating amount of a formulation to said patient.

30



## DETAILED DESCRIPTION OF THE INVENTION

### The Antitumor Agents

5       The present invention provides a composition and a method for treating mammalian cancer tumors, including human cancer tumors, particularly solid tumors. In this aspect of the invention, an effective amount of a compound having Formula I, as defined herein, contained in a citrate buffer solution, is administered to a mammal having a cancer tumor and in need of such treatment from about one half hour to about twenty-four hours before an  
10       effective amount of a chemotherapy agent to which the tumor is susceptible is administered to the mammal. Formula I and testing of a compound is described in U.S. Application Serial No. 125,609 filed on September 22, 1993, the disclosure of which in its entirety is incorporated herein by reference.

15       In the preparation of the formulation of the present invention, extensive studies were conducted to provide sufficient solubility of the cancer tumor compound and render the formulation stable on shelf-life as will become clear from the description that follows.

20       The present invention will be described in particular reference to tirapazamine formulations, however, it is to be understood that the other denoted compounds of the formula (I) are intended to be covered by the claims of the invention.

### Solubility Properties of Tirapazamine

The solubility of tirapazamine in water and various vehicles is shown in Table II.

25

TABLE II  
Solubility of Tirapazamine in Aqueous Media

Solvent	Temp°C	mg/ml
Water for Injections	20	1.43
Water for Injections	15	0.85
Normal Saline	15	0.85
Citrate buffer 0.05M pH 4 (isotonic)	15	0.81
Lactate buffer 0.1M pH 4 (isotonic)	15	0.90

TABLE II (contd.)  
Solubility of Tirapazamine in Aqueous Media

Solvent	Temp°C	mg/ml
Tween 80 0.2% w/v	15	0.9
Tween 80 20% w/v	15	1.02
Pluronic F68 20% w/v	15	1.08
Povidone (Kollidon 12PF) 10% w/v)	15	0.95
Albumin 4.5% w/v	20	1.33
Albumin 20% w/v	20	1.71
Glycerol 50% v/v in water	15	2.93
Glycerol	15	4.59
Propylene glycol 50% v/v in water	15	2.58
Propylene glycol	15	3.27
PEG 400 50% v/v in water	15	1.60
PEG 400	15	5.12
Dimethylformamide 25% v/v in water	15	1.83
1% Benzyl alcohol:10% ethanol:89% water, v/v	15	1.23
Ethanol 10% v/v in water	15	0.93
Ethanol 50% v/v in water	15	2.32
Ethanol 65% v/v in water	15	2.84
Ethanol 85% v/v in water	15	1.71
Ethanol	15	0.47

The limited solubility of 0.81 mg/ml would require up to a liter of fluid to be infused, therefore in order to minimize the fluid volume, solubility needed to be increased. Attempts to enhance the solubility by using surfactants (Tween 80) and polymers (Pluronic F68, Povidone, Albumin) were unsuccessful with minimal increase in solubility.

Solubility enhancement was achieved with co-solvents, however, the proportion of co-solvent necessary to solubilize the expected maximum tolerated dose of tirapazamine (~700 mg) would mean infusing significant quantities of co-solvent (for example up to 120 ml propylene glycol (PG) as 50% v/v PG/aqueous solution).

The physicochemical properties of tirapazamine demonstrate that the molecule is neither highly polar nor highly lipophilic in character. This is illustrated by (i) the partition coefficient (octanol/water) of 0.15 (logP -0.82) and (ii) the observed decomposition on melting at 200°C which suggests the crystal structure of tirapazamine is strongly bound by intermolecular forces. The planar nature of the molecule would facilitate an ordered stacking with the crystal with intermolecular attractions (charge transfer interactions) between each plane via the nitrogen and oxygen of the N-oxide functions. A hydrated form of tirapazamine can exist where water molecules are hydrogen bonded to the oxygen components.

To predict the solubility of compounds in water-solvent mixtures, various attempts have been made to classify organic solvents using parameters such as dielectric constant, solubility parameter, surface tension, interfacial tension, hydrogen bond donor and acceptor densities, and octanol-water partition coefficient. Values for selected solvents used in tirapazamine solubility studies are given in Table III. These parameters have been used mathematically to predict the solubility of nonpolar solutes by correlating these parameters with the slope of solubility plots constructed from experimental data. Those parameters that reflect the cohesive properties of solvents, such as solubility parameters and interfacial tension, result in the highest correlation with slope, as does the hydrogen bonding ability of the neat co-solvent expressed as the density of proton donating groups or acceptor groups.

TABLE III  
Polarity Indices of Solvents

(Rubino, J.T. and Yalkowsky, S.H., Cosolvency and Cosolvent Polarity,  
Pharmaceutical Research, 4 (1987) 220-230)

	Water	DMSO	DMF	DMA	GLYC	PG	PEG400
Dielectric constant	78.5	46.7	36.7	37.8	42.5	32.0	13.6
Solubility parameters	23.4	12.0	12.1	10.8	17.7	12.6	11.3
Interfacial tension dynes/cm	45.6	0.9	6.9	4.6	32.7	12.4	11.7
Surface tension dynes/cm	72.7	44.0	36.8	35.7	60.6	37.1	46.0
logP	-4.0	-1.4	-0.85	-0.66	-2.0	-1.0	---
Hydrogen bond donor density	111.0	0.0	0.0	0.0	41.1	27.4	5.6
Hydrogen bond acceptor density	11.0	28.2	38.7	32.3	82.2	54.4	50.8

wherein:

DMSO = dimethylsulphoxide

DMF = dimethylformamide

DMA = dimethylacetamide

GLYC=glycerol

PG = propylene glycol

PEG400 = polyethylene glycol 400

At high volume fractions aprotic solvents, e.g., dimethylsulphoxide (DMSO), dimethylformamide (DMF) and dimethylacetamide (DMA), disrupt the water structure through dipolar and hydrophobic effects. Amphiprotic solvents, e.g., glycerol, PEG 400 and propylene glycol (PG) can both self-associate and hydrogen bond with water, consequently, such solvents are not ideally suited for solutes that cannot participate in hydrogen bonding. The partition coefficient of the solute is an indicator for predicting whether co-solvents will be effective. The following equation has been used to successfully predict solubility in various solvent systems:

$$\log C_s = \log C_o = f(\log R + 0.89 \log P + 0.03)$$

where  $C_s$  and  $C_o$  are the solubilities in solvent mixture and water respectively,  $f$  is the co-solvent fraction,  $R$  is the relative solvent power (typical values being DMF = 4, glycerol = 0.5) and  $P$  is the partition coefficient. As  $P$  tends towards unity ( $\log P \Rightarrow 0$ ) then no increase in solubility is possible since,

$$\log C_s = \log C_o$$

Since  $\log P$  for tirapazamine is -0.8, this equation would predict that co-solvents are unlikely to have a significant effect on aqueous solubility. Experiments conducted with these co-solvents results in the finding that solubility of tirapazamine was not significantly enhanced by these co-solvents.

#### Stability

Stress studies were conducted using multiple autoclave cycles of 21 minutes at 121°C. These studies demonstrated that tirapazamine was more stable in acidic solutions of normal saline or solutions buffered to pH 4 using 0.05M citrate or 0.1M lactate buffer. Tirapazamine was unstable in the presence of phosphate buffer at pH 5.9 and in citrate buffer at pH 6. A shift in the normal saline formulation pH occurred after eight autoclave cycles from 4.5 to 4.9, therefore formulations required some degree of buffering.

Formulations were also stressed by storing at elevated temperatures of 50°C and 70°C after a single autoclave cycle of 21 minutes at 121°C. Tirapazamine was found to be unstable in the presence of lactate buffer after storage at 70°C. This instability was not apparent from multiple autoclave stressing. The most stable formulation was found to be 0.05M citrate pH 4.

Formulation of tirapazamine was therefore progressed using citrate buffer. Solubility of tirapazamine at 15°C required the concentration to be reduced from 1 to 0.5 mg/ml. Further stressing in citrate buffer at pH 3.5, 4.0 and 4.5 was conducted to determine the likely limits for pH. Based on data from this study the limits were set at pH 4.0 ± 0.3.

5

Based upon the stability data generated, the most stable formulation of tirapazamine was in citrate buffer at pH 4. The solubility of tirapazamine in citrate buffer was 0.81 mg/ml at 15°C. Therefore to limit the volume of infused liquid a maximum concentration of 0.7 mg/ml was used for further formulation development.

10

The effect of buffer concentration (0.05 or 0.005M) on stability was evaluated by stressing 2 x 10 L stability batches of tirapazamine (0.7 mg/ml) in citrate buffer at pH 4.0.

Tirapazamine was stable after 2 months in both 0.005M and 0.05M citrate buffer at 15 50°C. At 70°C, there was evidence of instability with the 0.05M citrate formulation, therefore the lower citrate concentration (0.005M) was chosen for development as the clinical formulation. The clinical formulation used in chemical studies discussed later was as follows:

20	Tirapazamine	0.700g
	Sodium Chloride	8.700g
	Citric Acid	0.9605g
	Sodium Hydroxide	0.2500g
	qs to pH 4.0 in water to 1000 ml.	

25 Tirapazamine is stored in clear glass 20 ml ampoules containing 0.7 mg/ml (14 mg) of tirapazamine in the isotonic citrate buffer. The ampoules are stored at 15°C to 30°C in light-proof packaging.

#### Dosing

30 An acute tolerance study in mice, single and multiple dose studies in rats and dogs and an *in vitro* myelosuppression study have been conducted with the formulation of the present invention.

In an acute tolerance study in the mouse, the LD<sub>10</sub> and LD<sub>50</sub> for tirapazamine were 35 found to be 98 and 101 mg/kg, respectively.

Single and 2-week and 2-month multiple-dose studies were performed in the rat and the dog. Clinical signs and symptoms observed in both species and each regimen included salivation, decreases in white blood cell measurements (including lymphocyte count in the dog), and decreases in red blood cell measurements.

5


#### Pharmacology

The effect of tirapazamine on a variety of aerobic and hypoxic cells has been studied in culture to measure the selectivity of tirapazamine cytotoxicity. Tirapazamine (20  $\mu$ M) was a potent and selective killer of hypoxic cells *in vitro*, with hypoxic cytotoxicity ratios of 150,  
10 119 and 52 for hamster, mouse and human cell lines, respectively (1-2 orders of magnitude greater than radiation sensitizers such as nitroimidazoles, mitomycin C and porfiromycin). This cytotoxicity was also observed over a range of oxygen tensions (1%-20% O<sub>2</sub>; primarily at 1%-4% O<sub>2</sub>).

15 *In vivo*, tirapazamine was equally effective in mouse tumor models as a single 0.30 mmol/kg (160mg/m<sup>2</sup>) dose or as multiple 0.08 mmol/kg (43 mg/m<sup>2</sup>) doses, when used with fractionated radiation (2.5 Gy x 8). Tirapazamine was also effective as a single 0.30 mmol/kg (160mg/m<sup>2</sup>) dose with a single large (20 Gy) dose of radiation. Tirapazamine appeared to be most effective, resulting in several cures in mouse SCCVII tumors, as multiple  
20 0.08 mmol/kg (43 mg/m<sup>2</sup>) doses given prior to each radiation fraction (2.5 Gy x 8); and tirapazamine appeared least effective, resulting in typically less than 1 log of cell kill, when given without radiation. When used with fractionated radiation, tirapazamine produced an effect equal to the effect predicted if tirapazamine were acting upon a separate cell population (hypoxic cells) than the radiation was acting upon (aerobic cells).

25

The mechanism of action of tirapazamine has been studied in detail and is closely tied to the metabolism of the drug. The illustration below portrays the proposed mechanism of action for tirapazamine-production of a free radical, during reduction to the mono-N-oxide, which causes single- and double-strand breaks in DNA. Under hypoxic conditions,  
30 tirapazamine is metabolized to the 2-electron reduction product WIN 64102 (mono-N-oxide; SR 4317) and then to the 4-electron reduction product WIN 60109 (zero-N-oxide; SR 4330). Several studies examining DNA damage repair following treatment with tirapazamine have shown the DNA repair inhibition to be dose-related and similar to that produced by x-rays.



The benzotriazine di-N-oxide tirapazamine was extensively studied both *in vitro* and *in vivo* to determine and quantify its effectiveness and to elucidate its mechanism of action.

5

#### In Vitro

The effects of tirapazamine on a variety of aerobic and hypoxic cells have been studied in culture to measure the selectivity of tirapazamine cytotoxicity. Chinese hamster ovary cells (CHO-HA-1), mouse cells (C3H 10T1/2, RIF-1, and SCCVII), and human cell lines (HCT-8, AG 1522, A549 and HT 1080) were used. Tirapazamine (20  $\mu$ M) was a potent and selective killer of hypoxic cells *in vitro* as shown in Table 4.

10

**TABLE 4**  
In Vitro Cytotoxicity of Tirapazamine to Eight Cell Lines Incubated Under Aerobic or Hypoxic Conditions

15

Cell line		Sensitivity Index <sup>b</sup>	IC <sub>50</sub> <sup>c</sup> ( $\mu$ M)	Hypoxic cytotoxicity ratio <sup>a</sup>	
Species	Name			Cell Line	Species Average
Hamster	CHO-HA-1 (normal <sup>d</sup> )	48	5	100-200	150
Mouse	RIF-1 (tumor)	30	3	80-100	119
	SCCVII (tumor)	39	4	160-200	
	C3H 10T1/2 (normal)	118	12	75-100	
Human	HCT-8 (tumor)	94	10	15-40	52
	A549 (tumor)	280	15	25-50	
	AG 1522 (normal)	190	13	50	
	HT 1080 (tumor)		22	100	



- a Hypoxic cytotoxicity ratio = Concentration of tirapazamine in air/Concentration of tirapazamine in nitrogen to yield approximately the same survival.
- b Sensitivity index = Time (in minutes) to reach  $10^{-2}$  (1%) surviving fraction at 20  $\mu$ M under hypoxic conditions.
- c IC<sub>50</sub> = Concentration required to inhibit cell growth by 50% in a 1-hour incubation under hypoxic conditions.
- d Normal = nontumorigenic.

10

### *In Vivo*

#### Tirapazamine Alone

When given alone *in vivo* in mice, tirapazamine-in single doses-would be expected to produce a relatively small cell kill corresponding to the percentage of tumor cells which are hypoxic. A number of experiments have shown this to be the case, with cell kills typically less than one log (surviving fraction  $\geq 1 \cdot 10^{-1}$ ). For example, the maximum cell kill observed following a single does was in the SCCVII tumor (surviving fraction =  $5 \cdot 10^{-1}$ ), and only a small tumor growth delay of 3 days was produced in the FSaIC fibrosarcoma.

20

Multiple doses of tirapazamine given without radiation, might be expected to produce slightly more cell killing than a single does, even at lower doses of tirapazamine. However, the lowest surviving fraction seen in four different mouse tumors was  $5 \cdot 10^{-1}$ , and down to  $5 \cdot 10^{-2}$  in a fifth mouse tumor (RIF-1 tumor).

25

#### Tirapazamine with Radiation

In a number of model systems described below, tirapazamine augments the antitumor activity of radiation, assessed by cell killing or tumor growth delay. Tumors tested include FSaIC, SCCVII, RIF-1, EMT6, and KHT. Tirapazamine augments cell kill when given on a single- or multiple-dose schedule, and when the drug is combined with either single-dose or fractionated radiation.

30

In one study, the antitumor effect of tirapazamine plus radiation exceeds the additive effect of these two treatments. Augmentation of activity by tirapazamine occurs when the drug is administered from 2.5 to 0.5 hours before radiation or up to 6 hours afterward. In addition to activity against hypoxic cells, tirapazamine radiosensitizes aerobic cells *in vitro* if the cells are exposed to the drug under hypoxic conditions either before or after radiation.

35

In one study, treatment with tirapazamine enhanced the antitumor activity of radiation to a greater extent than did the hypoxic cell sensitizer etanidazole.

The oxygen concentration/cytotoxicity curve of tirapazamine appears particularly well suited to combination with radiotherapy. Below approximately 30 torr (mm of Hg) cells become increasingly resistant to damaging effects of radiation. Nitroaromatic and quinone antibiotic radiosensitizers, however, are most effective only at much lower oxygen levels. Thus, they are not toxic to the moderately hypoxic, radioresistant cells present in tumors. By contrast, the cytotoxicity of tirapazamine remains relatively constant over the entire range of oxygen concentrations conferring radio-resistance.

Unlike other radiosensitizers studied to date, the toxicity of tirapazamine decreases at high oxygen concentrations (i.e., those found in normal tissue). In an *in vitro* system, the toxicity of tirapazamine was at least 50 to >2000 fold higher under hypoxia than under 100% oxygen vapor. Because it is active against a wide range of radio-resistant tumor cells but is not toxic to normal cells with high oxygen concentrations, tirapazamine is selectively cytotoxic to hypoxic tumor cells.

#### Tirapazamine with Chemotherapy

When tirapazamine (25 to 75 mg/kg IP=83.3 to 250 mg/m<sup>2</sup>) was administered to mice bearing the FSaIIc fibrosarcoma, some direct tumor cell killing was observed. Addition of tirapazamine (50 mg/kg IP = 167 mg/m<sup>2</sup>) to cyclophosphamide (150 mg/kg IP = 500 mg/m<sup>2</sup>), melphalan (10 mg/kg IP = 33 mg/m<sup>2</sup>), or cisplatin (10 mg/kg IP = 33 mg/m<sup>2</sup>) in this model produced 1.6- to 5.3-fold increases in tumor growth delay.

#### Effect on Normal Tissue

Female C3H/Km mice were used in two assays to examine the potential that tirapazamine might affect normal tissue sensitivity to ionizing radiation. Both normal skin reaction and leg (thigh) contraction tests were conducted with fractionated radiation. Tirapazamine did not affect the tissues in either assay.

To determine if tirapazamine might affect normal tissue, the right hind limbs of female C3H/Km mice were irradiated with eight fractions (3,4,5 or 6 Gy) over 4 days (once every 12 hours). The mice were injected with either saline or tirapazamine (0.08 mmol/kg=43 mg/m<sup>2</sup>) 30 minutes before, or immediately after each fraction. Skin reactions over the irradiated thighs were scored three times weekly, from Day 10 to Day 32 after the


first irradiation dose. The mice were scored "blinded" - with no knowledge of their treatment group-according to a scale similar to one developed previously [Brown JM, Goffinet DR, Cleaver JE, Kallman RF, "Preferential radiosensitization of mouse sarcoma relative to normal mouse skin by chronic intra-arterial infusion of halogenated pyrimidine analogs", JNCI 5 (1971) 47, 77-89]. No radiosensitization or additive toxicity was produced by the addition of tirapazamine to the radiation treatment as determined by skin reaction.

Having described the invention with reference to its preferred embodiments, it is to be understood that modifications within the scope of the invention will be apparent to those 10 skilled in the art.

## WHAT IS CLAIMED IS:

1. An aqueous parenteral formulation for the treatment of cancer tumors comprising:

5 an effective cancer tumor treating amount of a compound of the formula (I)



wherein X is H; hydrocarbyl (1-4C); hydrocarbyl (1-4C) substituted with OH, NH<sub>2</sub>, NHR or  
 10 NRR; halogen; OH; alkoxy (1-4C); NH<sub>2</sub>; NHR or NRR; wherein each R is independently  
 selected from lower alkyl (1-4C) and lower acyl (1-4C) and lower alkyl (1-4C) and lower  
 acyl (1-4C) substituted with OH, NH<sub>2</sub>, alkyl (1-4C) secondary and dialkyl (1-4C) tertiary  
 amino groups, alkoxy (1-4C) or halogen; and when X is NRR, both R's taken together  
 15 directly or through a bridge oxygen to form a morpholino ring, pyrrolidino ring or piperidino  
 ring;


n is 0 or 1; and

Y<sup>1</sup> and Y<sup>2</sup> are independently either H; nitro; halogen; hydrocarbyl (1-14C) including  
 cyclic and unsaturated hydrocarbyl, optionally substituted with 1 or 2 substituents selected  
 from the group consisting of halogen, hydroxy, epoxy, alkoxy (1-4C), alkylthio (1-4C),  
 20 primary amino (NH<sub>2</sub>), alkyl (1-4C) secondary amino, dialkyl (1-4C) tertiary amino, dialkyl  
 (1-4C) tertiary amino where the two alkyls are linked together to produce a morpholino,  
 pyrrolidino or piperidino, acyloxy (1-4C), acylamido (1-4C) and thio analogs thereof,  
 acetaminoalkyl (1-4C), carboxy, alkoxycarbonyl (1-4C), carbamyl, alkylcarbamyl (1-4C),  
 alkylsulfonyl (1-4C) or alkylphosphonyl (1-4C), wherein the hydrocarbyl can optionally be  
 25 interrupted by a single ether (-O-) linkage; or wherein Y<sup>1</sup> and Y<sup>2</sup> are independently either  
 morpholino, pyrrolidino, piperidino, NH<sub>2</sub>, NHR', NR'R'O(CO)R', NH(CO)R', O(SO)R', or  
 O(POR')R' in which R' is a hydrocarbyl (1-4C) which may be substituted with OH, NH<sub>2</sub>,  
 alkyl (1-4C) secondary amino, dialkyl (1-4C) tertiary amino, morpholino, pyrrolidino,  
 piperidino, alkoxy (1-4C), or halogen substituents, or pharmacologically acceptable salt of

said compound in a parenterally acceptable buffer having a concentration of from about 0.001M to about 0.1M.

2. A method of cancer tumor treatment of a patient in need of such treatment comprising administering an effective cancer tumor treating amount of a formulation to said patient in need of such treatment, said formulation comprising:

an effective cancer tumor treating amount of a compound of the formula (I)



10

wherein X is H; hydrocarbyl (1-4C); hydrocarbyl (1-4C) substituted with OH, NH<sub>2</sub>, NHR or NRR; halogen; OH; alkoxy (1-4C); NH<sub>2</sub>; NHR or NRR; wherein each R is independently selected from lower alkyl (1-4C) and lower acyl (1-4C) and lower alkyl (1-4C) and lower acyl (1-4C) substituted with OH, NH<sub>2</sub>, alkyl (1-4C) secondary and dialkyl (1-4C) tertiary amino groups, alkoxy (1-4C) or halogen; and when X is NRR, both R's taken together directly or through a bridge oxygen to form a morpholino ring, pyrrolidino ring or piperidino ring;

n is 0 or 1; and  
Y<sup>1</sup> and Y<sup>2</sup> are independently either H; nitro; halogen; hydrocarbyl (1-14C) including cyclic and unsaturated hydrocarbyl, optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, hydroxy, epoxy, alkoxy (1-4C), alkylthio (1-4C), primary amino (NH<sub>2</sub>), alkyl (1-4C) secondary amino, dialkyl (1-4C) tertiary amino, dialkyl (1-4C) tertiary amino where the two alkyls are linked together to produce a morpholino, pyrrolidino or piperidino, acyloxy (1-4C), acylamido (1-4C) and thio analogs thereof, acetylaminoalkyl (1-4C), carboxy, alkoxycarbonyl (1-4C), carbamyl, alkylcarbamyl (1-4C), alkylsulfonyl (1-4C) or alkylphosphonyl (1-4C), wherein the hydrocarbyl can optionally be interrupted by a single ether (-O-) linkage; or wherein Y<sup>1</sup> and Y<sup>2</sup> are independently either morpholino, pyrrolidino, piperidino, NH<sub>2</sub>, NHR', NR'R'O(CO)R', NH(CO)R', O(SO)R', or O(POR')R' in which R' is a hydrocarbyl (1-4C) which may be substituted with OH, NH<sub>2</sub>,


30

alkyl (1-4C) secondary amino, dialkyl (1-4C) tertiary amino, morpholino, pyrrolidino, piperidino, alkoxy (1-4C), or halogen substituents, or pharmacologically acceptable salt of said compound in a citrate buffer having a concentration of from about 0.005M to about 0.05M.

5

3. An aqueous parenteral formulation for the treatment of cancer tumors comprising:

of from about 0.500 to about 0.810 g of a compound of the formula (I)



10

wherein X is H; hydrocarbyl (1-4C); hydrocarbyl (1-4C) substituted with OH, NH<sub>2</sub>, NHR or NRR; halogen; OH; alkoxy (1-4C); NH<sub>2</sub>; NHR or NRR; wherein each R is independently selected from lower alkyl (1-4C) and lower acyl (1-4C) and lower alkyl (1-4C) and lower acyl (1-4C) substituted with OH, NH<sub>2</sub>, alkyl (1-4C) secondary and dialkyl (1-4C) tertiary amino groups, alkoxy (1-4C) or halogen; and when X is NRR, both R's taken together directly or through a bridge oxygen to form a morpholino ring, pyrrolidino ring or piperidino ring;

n is 0 or 1; and

20 Y<sup>1</sup> and Y<sup>2</sup> are independently either H; nitro; halogen; hydrocarbyl (1-14C) including cyclic and unsaturated hydrocarbyl, optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, hydroxy, epoxy, alkoxy (1-4C), alkylthio (1-4C), primary amino (NH<sub>2</sub>), alkyl (1-4C) secondary amino, dialkyl (1-4C) tertiary amino, dialkyl (1-4C) tertiary amino where the two alkyls are linked together to produce a morpholino, pyrrolidino or piperidino, acyloxy (1-4C), acylamido (1-4C) and thio analogs thereof, 25 acetyl aminoalkyl (1-4C), carboxy, alkoxycarbonyl (1-4C), carbamyl, alkylcarbamyl (1-4C), alkylsulfonyl (1-4C) or alkylphosphonyl (1-4C), wherein the hydrocarbyl can optionally be interrupted by a single ether (-O-) linkage; or wherein Y<sup>1</sup> and Y<sup>2</sup> are independently either morpholino, pyrrolidino, piperidino, NH<sub>2</sub>, NHR', NR'R'O(CO)R', NH(CO)R', O(SO)R', or 30 O(POR')R' in which R' is a hydrocarbyl (1-4C) which may be substituted with OH, NH<sub>2</sub>,

alkyl (1-4C) secondary amino, dialkyl (1-4C) tertiary amino, morpholino, pyrrolidino, piperidino, alkoxy (1-4C), or halogen substituents, or pharmacologically acceptable salt of said compound in a citrate buffer having a concentration of from about 0.005M to about 0.05M;

- 5 of from about 0.100 to about 9.000 g of sodium chloride;  
of from about 0.9000 to about 10.00 g of citric acid  
10 of from about 0.200 to about 3.000 g of sodium hydroxide; and  
qs to pH 3.0 - 5.0 in water to 1000 ml.
4. A method of cancer tumor treatment of a patient in need of such treatment comprising  
15 administering an effective cancer tumor treating amount of the formulation of claim 3.
5. An aqueous parenteral formulation for the treatment of cancer tumors comprising:  
an effective cancer tumor treating amount of 1,2,4-benzotriazine-3-amine 1,4-  
dioxide in a citrate buffer having a concentration of from about 0.005 M to about 0.05 M.  
20
6. The aqueous parenteral formulation of claim 5 wherein said citrate buffer has a pH of  
from about 3.7 to 4.3.
7. A method of cancer tumor treatment of a patient in need of such treatment comprising  
25 administering an effective cancer tumor treating amount of the formulation of claim 5.
8. An aqueous parenteral formulation for the treatment of cancer tumors comprising:  
of from about 0.500 to about 0.810 g of 1,2,4-benzotriazine-3-amine 1,4-  
dioxide;  
30 of from about 5.000 to about 9.000 g of sodium chloride;  
of from about 0.9000 to about 10.00 g of citric acid  
35 of from about 0.200 to about 3.000 g of sodium hydroxide; and  
qs to pH 3.7 - 4.3 in water to 1000 ml.

9. A method of cancer tumor treatment of a patient in need of such treatment comprising administering an effective cancer tumor treating amount of the formulation of claim 8.

10. An aqueous parenteral formulation for the treatment of cancer tumors comprising:

5 0.700 g of 1,2,4-benzotriazine-3-amine 1,4-dioxide;

8.700 g of sodium chloride;

0.9605 g of citric acid;

0.2500 g of sodium hydroxide; and

10 qs to pH 4 in water to 1000 ml.

11. A method of cancer tumor treatment of a patient in need of such treatment comprising administering an effective cancer tumor treating amount of the formulation of claim 10.



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/13550

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/53

US CL : 514/243

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/243

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A 3,980,779 (LEY ET AL.) 14 September 1976, see entire document.	1-11
X	US, A, 5,175,287 (LEE ET AL.) 29 December 1992, see entire document.	1-11

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
* "A" document defining the general state of the art which is not considered to be of particular relevance	* "T" later documents published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* "E" earlier document published on or after the international filing date	* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* "O" document referring to an oral disclosure, use, exhibition or other means	* "G" document member of the same patent family
* "P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 NOVEMBER 1996

Date of mailing of the international search report

12 DEC 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JEROME D. GOLDBERG *atc*

Telephone No. (703) 308-1235